Janus Henderson Group PLC Increases Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Janus Henderson Group PLC lifted its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 21.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,080,367 shares of the company’s stock after acquiring an additional 368,908 shares during the quarter. Janus Henderson Group PLC owned 0.06% of Entrada Therapeutics worth $36,011,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in TRDA. Barclays PLC grew its position in Entrada Therapeutics by 210.6% in the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock worth $720,000 after purchasing an additional 30,585 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Entrada Therapeutics in the 4th quarter worth $36,000. SG Americas Securities LLC grew its holdings in shares of Entrada Therapeutics by 44.0% in the fourth quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock worth $243,000 after acquiring an additional 4,291 shares during the period. LPL Financial LLC increased its position in Entrada Therapeutics by 12.9% during the fourth quarter. LPL Financial LLC now owns 55,154 shares of the company’s stock valued at $954,000 after acquiring an additional 6,310 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Entrada Therapeutics by 22.1% during the fourth quarter. Legal & General Group Plc now owns 19,899 shares of the company’s stock valued at $344,000 after acquiring an additional 3,601 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Entrada Therapeutics Trading Down 8.4%

Shares of TRDA stock opened at $7.97 on Thursday. Entrada Therapeutics, Inc. has a 12 month low of $7.10 and a 12 month high of $21.79. The stock has a market cap of $302.49 million, a P/E ratio of 5.01 and a beta of 0.04. The company has a 50 day simple moving average of $9.04 and a two-hundred day simple moving average of $13.58.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million during the quarter, compared to analyst estimates of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.